Incyte Corp Company Profile
✉ Email this page to a colleague
What is the competitive landscape for INCYTE CORP, and when can generic versions of INCYTE CORP drugs launch?
INCYTE CORP has three approved drugs.
There are twenty-four US patents protecting INCYTE CORP drugs.
There are three hundred and ninety-six patent family members on INCYTE CORP drugs in fifty countries and forty-one supplementary protection certificates in eighteen countries.
Drugs and US Patents for Incyte Corp
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Incyte Corp | OPZELURA | ruxolitinib phosphate | CREAM;TOPICAL | 215309-001 | Sep 21, 2021 | RX | Yes | Yes | 11,590,138 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Incyte Corp | OPZELURA | ruxolitinib phosphate | CREAM;TOPICAL | 215309-001 | Sep 21, 2021 | RX | Yes | Yes | 11,590,136 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Incyte Corp | JAKAFI | ruxolitinib phosphate | TABLET;ORAL | 202192-002 | Nov 16, 2011 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Incyte Corp | PEMAZYRE | pemigatinib | TABLET;ORAL | 213736-002 | Apr 17, 2020 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Incyte Corp | OPZELURA | ruxolitinib phosphate | CREAM;TOPICAL | 215309-001 | Sep 21, 2021 | RX | Yes | Yes | 9,974,790*PED | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Incyte Corp | JAKAFI | ruxolitinib phosphate | TABLET;ORAL | 202192-005 | Nov 16, 2011 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Incyte Corp | JAKAFI | ruxolitinib phosphate | TABLET;ORAL | 202192-004 | Nov 16, 2011 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Paragraph IV (Patent) Challenges for INCYTE CORP drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Tablets | 5 mg, 10 mg, 15 mg, 20 mg, and 25 mg | ➤ Subscribe | 2015-12-17 |
International Patents for Incyte Corp Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Spain | 2700433 | ⤷ Try a Trial |
Brazil | PI0814254 | ⤷ Try a Trial |
European Patent Office | 2348023 | ⤷ Try a Trial |
European Patent Office | 4309737 | ⤷ Try a Trial |
San Marino | T201600172 | ⤷ Try a Trial |
Canada | 3153076 | ⤷ Try a Trial |
South Korea | 20220079550 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Incyte Corp Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1966202 | CA 2013 00005 | Denmark | ⤷ Try a Trial | |
1966202 | 1390005-5 | Sweden | ⤷ Try a Trial | PRODUCT NAME: RUXOLITINIB, ELLER ETT FARMACEUTISKT GODTAGBART SALT DAERAV; REG. NO/DATE: EU/1/12/773/001; 2012-08-23; PERIOD OF VALIDITY (FROM - UNTIL): 2026-12-13 - 2027-08-27 |
2455382 | PA2017012 | Lithuania | ⤷ Try a Trial | PRODUCT NAME: RUKSOLITINIBAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA; REGISTRATION NO/DATE: EU/1/12/773/001-006 20150311 |
2861595 | LUC00222 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: PEMIGATINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; AUTHORISATION NUMBER AND DATE: EU/1/21/1535 20210329 |
2861595 | 21C1041 | France | ⤷ Try a Trial | PRODUCT NAME: PEMIGATINIB OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/21/1535 20210329 |
1966202 | 2013C/014 | Belgium | ⤷ Try a Trial | PRODUCT NAME: RUXOLITINIB; AUTHORISATION NUMBER AND DATE: EU/1/12/773/001 20120828 |
2861595 | 122021000054 | Germany | ⤷ Try a Trial | PRODUCT NAME: PEMIGATINIB ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ DAVON; REGISTRATION NO/DATE: EU/1/21/1535 20210326 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.